Skip to main content
TipRanks
Go Ultimate75% OFF

Bio-Techne (TECH) AI Stock Analysis

536 Followers
TECH

Bio-Techne

(NASDAQ:TECH)

Select Model
Rating:74Outperform
Price Target:$82.00â–²(12.71% Upside)
Action:reiterated
Date:11/07/26

The score is driven primarily by strong financial quality (healthy margins, low leverage, and strong free cash flow), supplemented by a constructive technical trend and a favorable M&A catalyst that improves near-term outcome visibility. These positives are meaningfully offset by expensive valuation (high P/E and low dividend yield), which limits upside without continued execution.

Positive Factors
Strong profitability and cash generationHigh gross, operating, and EBITDA margins indicate meaningful operating strength, while strong free cash flow shows that earnings are largely converting into cash. This combination supports reinvestment, resilience through demand changes, and sustained funding for product and platform development.
Negative Factors
Limited recent revenue growthLow-single-digit quarterly growth and flat full-year sales indicate that expansion in the core business has remained restrained. Slower top-line growth can limit operating leverage, reduce the pace of reinvestment, and make future earnings improvement more dependent on margin actions.

Bio-Techne Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down sales across regions so you can see where the company’s demand is strongest and where it faces exposure to local economic cycles, regulatory changes, or currency swings. Helps gauge geographic diversification and where future growth or risk is concentrated.

$0.00$100.00M$200.00M$300.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25
Chart Insights

Bio-Techne's revenue growth in the United States and EMEA regions remains robust, reflecting strong demand in biopharma markets. Greater China shows signs of recovery with low double-digit growth, aligning with earnings call optimism about stabilization. However, the Rest of World and UK regions face challenges, possibly due to geopolitical and funding uncertainties. The strategic divestiture of Exosome Diagnostics is expected to enhance margins, supporting future profitability despite current market uncertainties.

Data provided by:The Fly

Bio-Techne (TECH) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%TECH+18.88%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$11.41B
Dividend Yield
0.55%
Average Volume (3M)
2.89M
Price to Earnings (P/E)
66.1
Beta (1Y)
0.84
Revenue Growth
0.94%
EPS Growth
122.38%
Country
US
Employees
3,000
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Bio-Techne Business Overview & Revenue Model

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments,...

How the Company Makes Money

Bio-Techne makes money primarily by selling life-science research and diagnostic products and, to a lesser extent, associated services. Key revenue streams include: (1) Consumable reagents used repeatedly in lab workflows—such as recombinant proteins...

Bio-Techne Earnings Call Summary

Earnings Call Date:May 06, 2026(Q3-2026)|% Change Since:28.88%|Next Earnings Date:Feb 02, 2027
Earnings Call SentimentPositive

The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.

Positive Updates

Strong Spatial Biology Momentum and COMET Backlog
Spatial Biology delivered mid-teens growth overall with the COMET Multiomic Spatial Platform growing more than 65% in the quarter; company exited the quarter with a record COMET backlog and installed the first COMET system in China, positioning the platform for continued scaling.

Negative Updates

Overall Revenue Decline
Total revenue for Q3 was $311.4 million, decreasing 2% on both an organic and reported basis; foreign exchange was a 2% tailwind while prior divestiture and timing effects together created notable headwinds.

Company Guidance

Bio‑Techne said it expects Q4 organic revenue to be approximately flat, with underlying growth across the rest of the portfolio running at low single digits once the company‑specific GMP/cell‑therapy timing headwind (which will moderate to ~150 basis points in Q4 and be fully lapped in FY‑2027) is excluded; management also reiterated that the prior quarter suffered a ~400‑bp timing headwind, that biotech funding has rebounded (+90% and +50% in recent fiscal Q2 and Q3) with a typical 2–3 quarter lag to spending, and that they intend to expand Q4 margins by roughly 100 basis points year‑over‑year (building on Q3 adjusted operating margin of 34.2%, a 310‑bp sequential improvement, and adjusted gross margin of 70.4%); longer term they said they would be disappointed if FY‑2027 did not deliver at least mid‑single‑digit growth as company‑specific headwinds roll off and funding translates to customer spend.

Bio-Techne Financial Statement Overview

Summary

Strong overall fundamentals supported by solid profitability (TTM gross margin ~66%, operating margin ~16%, EBITDA margin ~25%), conservative leverage (TTM debt-to-equity ~0.13), and robust/free-cash-flow generation (TTM FCF ~$308M). The main risk is uneven year-to-year profitability/returns and slightly weaker recent cash-flow coverage versus prior annual periods, suggesting some sensitivity to mix/timing.

Income Statement

76Positive

Balance Sheet

84Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue1.23B1.22B1.22B1.16B1.14B1.11B
Gross Profit807.58M799.07M790.27M769.73M769.82M756.50M
EBITDA328.77M343.44M216.88M313.14M457.11M413.76M
Net Income171.97M181.86M73.40M168.10M285.26M272.05M
Balance Sheet
Total Assets2.64B2.59B2.56B2.70B2.64B2.29B
Cash, Cash Equivalents and Short-Term Investments351.13M264.71M162.19M152.86M204.31M247.03M
Total Debt285.56M289.09M444.06M419.54M454.96M325.97M
Total Liabilities471.13M478.50M639.06M635.02M672.18M593.79M
Stockholders Equity2.17B2.11B1.92B2.07B1.97B1.70B
Cash Flow
Free Cash Flow308.20M263.22M256.55M236.10M216.15M280.36M
Operating Cash Flow337.60M292.07M287.56M298.98M254.39M325.27M
Investing Cash Flow-22.72M-18.19M-35.18M-203.03M-265.65M-96.85M
Financing Cash Flow-108.53M-169.11M-253.91M-122.40M22.62M-242.85M

Bio-Techne Technical Analysis

Technical Analysis SentimentPositive
Last Price72.75

Price Trends

50DMA72.47Positive
100DMA72.10Positive
200DMA63.31Positive

Market Momentum

MACD0.09Positive
RSI52.22Neutral
STOCH48.60Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Positive. The current price of 72.75 is above the 20-day moving average (MA) of 72.64, above the 50-day MA of 72.47, and above the 200-day MA of 63.31, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 52.22 is Neutral, neither overbought nor oversold. The STOCH value of 48.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TECH.

Bio-Techne Risk Analysis

Bio-Techne disclosed 31 risk factors in its most recent earnings report. Bio-Techne reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The proposed acquisition of the Company by Merck KGaA, Darmstadt, Germany may disrupt or adversely affect our business, prospects, financial condition and results of operations.Q2, 2026
2.The Merger may not be completed within the expected timeframe, or at all, and a significant delay in or the failure to complete the Merger could adversely affect our business and the market price of our common stock.Q2, 2026
3.The Merger Agreement contains provisions that could discourage a potential competing acquirer of the Company or could result in a competing proposal being made at a lower price than it otherwise might have been.Q2, 2026

Bio-Techne Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TECH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TECHTECH74Outperform$11.41B66.088.22%0.55%0.94%122.38%
ADPTADPT64Neutral$4.61B-62.93-37.40%―17.91%16.01%
ABCLABCL57Neutral$3.60B-23.08-15.35%―92.10%16.43%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ABSIABSI50Neutral$1.31B-9.50-60.84%―-47.18%12.12%
MRVIMRVI48Neutral$1.89B-16.31-31.86%―10.77%46.91%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%TECHADPTMRVIABCLABSIKLRADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TECH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TECHBio-Techne72.7514.3424.54%
ADPTAdaptive Biotechnologies28.4612.1474.39%
MRVIMaravai Lifesciences Holdings, Inc.7.383.96115.79%
ABCLAbcellera Biologics, Inc.11.027.61223.17%
ABSIAbsci Corp.8.185.41195.31%
KLRAKailera Therapeutics, Inc.11.79-14.21-54.65%

Bio-Techne Corporate Events

DividendsM&A Transactions

Bio-Techne Declares Quarterly Dividend Amid Merck Transaction

Neutral
Nov 4, 2026

On November 3, 2026, Bio-Techne said its board had decided to pay a $0.08-per-share dividend for the quarter ended September 30, 2026. The dividend was scheduled for November 23 to shareholders of record on November 13, provided the company’s transac...

Business Operations and StrategyM&A TransactionsShareholder Meetings

Bio-Techne Shareholders Approve Merck Acquisition Agreement

Positive
Sep 23, 2026

On September 23, 2026, Bio-Techne shareholders approved the Agreement and Plan of Merger under which Merck KGaA, Darmstadt, Germany will acquire the company, following a special meeting where 78.55% of eligible shares were represented and the merger...

Legal ProceedingsM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings

Bio-Techne Supplements Merger Proxy Amid Shareholder Litigation

Neutral
Sep 14, 2026

Bio-Techne Corporation, a Minnesota-based life sciences tools and diagnostics provider, supplies specialized reagents, instruments and analytical technologies to biopharma, academic and clinical customers worldwide. Its portfolio underpins drug disco...

Business Operations and StrategyFinancial DisclosuresM&A Transactions

Bio-Techne reports stronger profitability in fiscal Q4 2026

Positive
Aug 12, 2026

Bio-Techne reported fourth-quarter fiscal 2026 results on August 12, 2026, showing modest top-line growth but stronger profitability, as organic revenue rose 3% to $321.2 million while GAAP EPS swung to $0.35 from a loss a year earlier and full-year...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026